This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Figulla, H. R. Articles by Kreuzer, H. Search for Related Content PubMed PubMed Citation Articles by Figulla, H. R. Articles by Kreuzer, H.

Circulation, Vol 76, 208-216, Copyright © 1987 by American Heart Association

ARTICLES

Inhomogenous capillary flow and its prevention by verapamil and hydralazine in the cardiomyopathic Syrian hamster

HR Figulla, F Vetterlein, M Glaubitz and H Kreuzer

There is clinical evidence that human dilated cardiomyopathy is related to microcirculatory disorders. We used an experimental preparation of the disease that consisted of a study of the microcirculation of 45 cardiomyopathic Syrian and 18 control hamsters with timed plasma staining. To investigate dynamic vascular disorders a double injection technique was used that permitted demonstration of all permanently and temporarily perfused capillaries in the same animal. The results showed a total capillary density of 3423 +/- 470 capillaries/mm2 in the cardiomyopathic hamster during the premyocytolic phase (30 days of age) and that of 3289 +/- 506 capillaries/mm2 during the myocytolytic phase (44 days). These values were not significantly different from those in the control group (3349 +/- 473 capillaries/mm2 at 30 days and 3383 +/- 556 capillaries/mm2 at 44 days). However, tissue areas with extended coronary transit times were detected only in the cardiomyopathic hamsters. These areas were of the same individual and cumulative size at 30 days (diameter approximately 200 micron, 4% of the tissue) as the myocytolytic zones at 44 days. In cardiomyopathic hamsters verapamil and hydralazine prevented both hypoperfusion and myocytolysis. The results favor the view that microcirculatory disorders generate tissue damage in the cardiomyopathic hamster and that these disorders can be prevented through treatment with the calcium antagonist verapamil or with the vasodilator hydralazine.

This article has been cited by other articles:

				K. Komamura, R. Tatsumi, J.-i. Miyazaki, K. Matsumoto, E. Yamato, T. Nakamura, Y. Shimizu, T. Nakatani, S. Kitamura, H. Tomoike, et al. Treatment of Dilated Cardiomyopathy With Electroporation of Hepatocyte Growth Factor Gene Into Skeletal Muscle Hypertension, September 1, 2004; 44(3): 365 - 371. [Abstract] [Full Text] [PDF]

				H. Kumamoto, H. Okamoto, M. Watanabe, H. Onozuka, K. Yoneya, I. Nakagawa, S. Chiba, S. Watanabe, T. Mikami, K. Abe, et al. Beneficial effect of myocardial angiogenesis on cardiac remodeling process by amlodipine and MCI-154 Am J Physiol Heart Circ Physiol, April 1, 1999; 276(4): H1117 - H1123. [Abstract] [Full Text] [PDF]

				Y. Watanabe, H. Kusuoka, K. Fukuchi, T. Fujiwara, and T. Nishimura Contribution of hypoxia to the development of cardiomyopathy in hamsters Cardiovasc Res, August 1, 1997; 35(2): 217 - 222. [Abstract] [Full Text] [PDF]

				M. Veronneau, M. Tanguay, E. Fontaine, G. Jasmin, and L. Dumont Reactivity to endothelium-dependent and -independent vasoactive substances is maintained in coronary resistance vessels of the failing hamster heart Cardiovasc Res, March 1, 1997; 33(3): 623 - 630. [Abstract] [PDF]

				H. R. Figulla, F. Gietzen, U. Zeymer, M. Raiber, J. Hegselmann, R. Soballa, and R. Hilgers Diltiazem Improves Cardiac Function and Exercise Capacity in Patients With Idiopathic Dilated Cardiomyopathy: Results of the Diltiazem in Dilated Cardiomyopathy Trial Circulation, August 1, 1996; 94(3): 346 - 352. [Abstract] [Full Text]

				C. G. Gustavsson, S. U. Persson, H. Larsson, and S. Persson Changed Blood Rheology in Patients With Idiopathic Dilated Cardiomyopathy Angiology, February 1, 1994; 45(2): 107 - 111. [Abstract] [PDF]